Conference Presentation, Fireside Chat
Conversation with FDA Commissioner Marty Makary & CMS Admin Mehmet Oz | Future of Health Summit 2025
- Drug pricing is projected to undergo massive reductions rather than typical single-digit percent changes, driven by voluntary industry adoption of most favored nation mechanisms and specific regulations targeting skin substitutes, which are expected to prevent cost escalations from $100 to $5,000 and curb a market growth projection of $250 million to $23 billion next year.
- Biosimilar and drug development timelines are targeted for significant compression, reducing market entry times from 5–8 years to 2.5–5 years for biosimilars and shaving six years off general drug development timelines through the elimination of animal testing via computational modeling, with cost reductions for biosimilars estimated at $100 million or more per medication.
- Regulatory review speeds will be accelerated by implementing an agency-wide AI tool for all reviewers by June 30th, issuing national priority review vouchers within hours of contact for companies with game-changing products, and transitioning from separate giant applications to continuous trials, while aiming to cut idle time to ensure all user fee deadlines and funding goals are met.
- A $50 billion rural transformation fund is expected to be distributed by year-end to incentivize all 50 states to apply, complemented by a separate funding mechanism providing an additional $10 billion annually for five years (a 50% increase) to support rural healthcare innovations.
- The administration plans to bolster domestic supply chains for active pharmaceutical ingredients and raw materials through CMS funding incentives and FDA risk highlighting to address national security concerns, alongside a plan to recruit top-tier engineers on two-year contracts to fix specific problems.
- Data interoperability and digital transformation initiatives include a growth in data pledge signatories from 60 to 450 companies, the launch of a free national provider directory, and the deployment of AI tools for data authentication by June 30th, with a new platform called "Trump Rx" expected to be functional by early next year to mark domestically made generic drugs.
- Administrative efficiency and cost management targets include a projection that administrative costs comprise 12% of the $1.75 trillion managed by CMS and that fraud, waste, and abuse account for roughly 8% ($100 billion) of the total healthcare bill, with private sector insurance companies expected to resolve prior authorization processes under continued pressure.
- The average Medicare beneficiary is projected to face a $40 premium increase next year, while overall growth rates for the private sector commercial and Medicare segments are estimated at roughly 9%, alongside the removal of nine petroleum-based food dyes within weeks and immediate payment coverage for a new autism drug indication.
- A new rule scheduled for January 1st will disallow the sale of previously permitted skin substitutes, and the government intends to eliminate the one-year delay in safety signal discovery by monitoring big data immediately upon drug approval, aiming to rebuild public trust which has fallen from 71% in 2019 to 40%.
- New drug reforms are scheduled to be announced within the next three months, including potential bans on imported raw materials to facilitate onshoring, the consolidation of drug and device reviews where CMS determines coverage, and the implementation of continuous trials to replace separate phase applications.